Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

  title={Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.},
  author={Andrew W. Roberts and Matthew S. Davids and John M. Pagel and Brad S. Kahl and Soham D. Puvvada and John F Gerecitano and Thomas J. Kipps and Mary Ann Anderson and Jennifer R. Brown and Lori A. Gressick and Shekman L. Wong and Martin Dunbar and Ming Zhu and Monali Desai and E. Cerri and Sari Heitner Enschede and Rod A. Humerickhouse and William G. Wierda and John Francis Seymour},
  journal={The New England journal of medicine},
  volume={374 4},
BACKGROUND New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells. METHODS We conducted a phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL or small lymphocytic lymphoma (SLL) to assess safety, pharmacokinetic profile, and efficacy. In the dose… 

Figures and Tables from this paper

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Venetoclax as a long-term continuous therapy is generally well tolerated in patients with R/R CLL when initiated with the current treatment algorithm.

Phase I First-inHuman Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Selective targeting of BCL-2 with venetoclax was well tolerated, and single-agent activity varied among NHL subtypes, and 1,200 mg was determined to be the recommended single- agent dose for future studies in FL and DLBCL.

Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia

This review focuses on venetoclax, its mechanism of action, pharmacology, and clinical trial data and seeks to place it in the context of rapid advances in therapy for patients with relapsed CLL, especially those with del(17p) CLL.

Venetoclax for the treatment of patients with chronic lymphocytic leukemia.

Trials suggest that venetoclax induces deeper and more durable responses when used in combination with rituximab, and combination studies with other agents are ongoing, and Phase III trials are also underway, and will provide data on the efficacy and safety of venetClax in combinationWith monoclonal antibodies and targeted therapies in larger patient populations.

Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists.

The rapidity with which ALC drops helps predict TLS and could help guide dose-escalation decisions, and venetoclax RDE with close in-hospital monitoring at experienced centers and in select patients is feasible.

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Among patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of progression‐free survival than bendamustine plus r ituximac, and the benefit was maintained across all clinical and biologic subgroups.

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Selective targeting of BCL-2 with venetoclax was well tolerated, and single-agent activity varied among NHL subtypes, and 1,200 mg was determined to be the recommended single- agent dose for future studies in FL and DLBCL.

A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy

The study establishes the safety and efficacy of flavopiridol as consolidation therapy after chemoimmunotherapy for patients with CLL and further evaluation is required in larger trials for the utility of CDK inhibitors as consolidation or maintenance strategies.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Patients without bulky lymphadenopathy, BCRi-refractory CLL, or an adverse mutation profile had the most durable benefit, and venetoclax was superior for patients achieving CR/CRi or U-MRD in landmark analyses.



Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

The combination of idelalisib and rituximab, as compared with placebo and r ituximabs, significantly improved progression-free survival, response rate, and overall survival among patients with relapsed CLL who were less able to undergo chemotherapy.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL.

Risk categories and refractory CLL in the era of chemoimmunotherapy.

Recent results that may lead to a reassessment of risk categories in CLL focusing on fit patients who are eligible for all treatment options are discussed and how emerging data on treatment failure from large trials using chemoimmunotherapy may help to define risk groups inCLL is discussed.

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

Sequencing data confirm initial reports associating mutations in BTK and PLCG2 with progression and clearly show that CLL progressions are associated with these mutations, while RT is likely not, and shows poor prognosis after discontinuation.

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.

Most patients with RR-CLL who discontinued ibrutinib early were difficult to treat and had poor outcomes.

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

  • K. FischerP. Cramer C. Wendtner
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
Chemoimmunotherapy with BR is effective and safe in patients with relapsed CLL and has notable activity in fludarabine-refractory disease, and promising results encouraged us to initiate a further phase II trial evaluating the BR regimen.

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

BCL2 is a valid therapeutic target in CLL, and its inhibition by navitoclax warrants further evaluation as monotherapy and in combination in this disease.

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

Evidence is provided that ibrutinib controls CLL disease manifestations and is well tolerated for an extended period; this information can help direct potential treatment options for different subgroups to diminish the long-term risk of relapse.

Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience

Bendamustine + rituximab (BR) was the most frequently used second‐line regimen, followed by alemtuzumab‐based regimens, R‐CHOP, and FCR, and appears to be an effective salvage regimen in this series, both in terms of progression‐free and overall survival.